I don’t think I was on the cutting edge of discovering Stupp’s change. But if you ask me I believe it would be a conflict to continue advising NVCR while taking a gig with NWBO and apparently he saw a better opportunity to be involved with NWBO at this time. Not sure it is anything more than that.
As for his likely work, I think it would primarily be around ensuring that the synthetic placebo arm is seen as valid and not an issue. That would be his strongest role and he would also be isolated from the group reviewing the unblinded trial results in my opinion, if he performed that role. He created the standard of care, so having him create the synthetic placebo characterizing the standard of care makes the most sense to me.
Market Data 
Markets 
AI
